Bank of America Securities issued a research report stating that it expects ALI HEALTH's revenue for fiscal year 2026 to meet expectations. Considering the company's investments in artificial intelligence and innovative drug sales since the second half of the year, the firm has revised its forecast for ALI HEALTH's adjusted net profit for fiscal 2026 down to a year-on-year increase of 20% (previously expected to grow by 35%). The bank has lowered ALI HEALTH's target price from HK$6.56 to HK$6, while reaffirming its "Buy" rating.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments